Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …

Background Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved
for the treatment of locally advanced or metastatic urothelial carcinoma in adults with …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial
carcinoma, but positive randomised data supporting their use as a first-line treatment are …

Background Patients with advanced urothelial carcinoma that progresses after platinum-
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with …

Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …